{
  "source": "PA-Notification-Ingrezza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1235-10\nProgram Prior Authorization/Notification\nMedication Ingrezza® (valbenazine)\nP&T Approval Date 11/2017, 11/2018, 11/2019, 11/2020, 6/2021, 6/2022, 6/2023, 10/2023,\n4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nIngrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment\nof adults with tardive dyskinesia and chorea associated with Huntington’s disease.1\n2. Coverage Criteriaa:\nA. Tardive Dyskinesia\n1. Initial Authorization\na. Ingrezza will be approved based on the following criterion:\n(1) Diagnosis of tardive dyskinesia\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Ingrezza therapy\nAuthorization will be issued for 12 months.\nB. Chorea associated with Huntington’s disease\n1. Initial Authorization\na. Ingrezza will be approved based on the following criterion:\n(1) Diagnosis of chorea associated with Huntington's disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Ingrezza therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\n© 2025 UnitedHealthcare Services Inc.\n1\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits, Step Therapy, and/or Medical Necessity may be in place.\n4. References:\n1. Ingrezza [package insert]., San Diego, CA: Neurocrine Biosciences, Inc.; February 2025\nProgram Prior Authorization/Notification - Ingrezza (valbenazine)\nC",
    " Necessity may be in place.\n4. References:\n1. Ingrezza [package insert]., San Diego, CA: Neurocrine Biosciences, Inc.; February 2025\nProgram Prior Authorization/Notification - Ingrezza (valbenazine)\nChange Control\n11/2017 New program\n11/2018 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n11/2019 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n11/2020 Annual review. Updated reference.\n6/2021 Added Ingrezza exclusion statement. Updated reference.\n6/2022 Annual review. No updates.\n6/2023 Annual review. Updated reference.\n10/2023 Added criteria for chorea associated with Huntington's disease. Updated\nbackground and reference.\n4/2024 Removed notation that Ingrezza is typically excluded.\n4/2025 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}